The role of thiotepa in allogeneic stem cell transplantation in patients with leukemia

Leukemia Research

Volumn 23, Issue 10, 1999, Pages 947-952

  Rosales, Finlander ^a   Naparstek, Elizabeth ^a   Varadi, Gabor ^a   Or, Reuven ^a   Slavin, Shimon ^a   Nagler, Arnon ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Allogeneic stem cell transplantation; Busulfan; Cyclophosphamide; Leukemia; Thiotepa

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; THIOTEPA;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOTRANSPLANTATION; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; MALE; MULTIPLE MYELOMA; ORAL DRUG ADMINISTRATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; STEM CELL TRANSPLANTATION;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; BUSULFAN; CHILD; CHILD, PRESCHOOL; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, HOMOLOGOUS;

EID: 0032820921     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(99)00112-5     Document Type: Article

References (38)

1. Slavin S., Nagler A. New developments in bone marrow transplantation. Curr. Opin. Oncol. 3:1991;254.
2. Varadi G., Nagler A. Conditioning regimens in autologous bone marrow transplantation. Clin. Immunother. 2:1994;342.
3. Thomas E.D., Buckner C.D., Banaji M., Clift R.A., Goodel B.W. One hundred patients with leukemia treated by chemotherapy, total body irradiation and allogeneic marrow transplantation. Blood. 49:1977;51.
4. Santos G.W. The development of busulfan-cyclophosphamide preparative regimens. Sem. Oncol. 20:1993;12.
5. Tutsha P.J., Copelan E.A., Klein J.P. Bone marrow transplantation for leukemia following a new busulfan-cyclophosphamide regimen. Blood. 70:1987;1382.
6. Santos G.W., Tutshka P.J., Broomeyer R., Sarai R., Beschorner W.E., Bias W.B. et al. Bone marrow transplant for acute nonlymphocytic leukemia after treatment with busulfan-cyclophosphamide. New Engl. J. Med. 309:1983;1347.
7. Buckner C.D., Demire T., Appelbaum F.R., Lambert K., Bensinger W.L., Clift R. et al. Busulfan-cyclophosphamide and total body irradiation for allogeneic marrow transplantation in advanced acute myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transpl. 17:1996;341.
8. Niederwieser D., Franema A., Herman J., Kolb H.J., Zwaun F., Gratwohl A. Poor response to induction chemotherapy is an indicator of poor survival after bone marrow transplantation for acute lymphoblastic leukemia. Bone Marrow Transpl. 4:1992;559.
9. Miller C., Wagner J.E., Vogelsang G.B. A randomized trial of busulfan cyclophosphamide and total body irradiation as preparative regimen for patients with chronic myelogenous leukemia. Blood. 80:1992;291.
10. Storb R. Critical issues in bone marrow transplantation. Transpl. Proc. 19:1987;2774.
11. Nag S., Waxman D. Thiotepa oxygenation by constitutive hepatic P450 enzyme and drug modulation of metabolism and clearance in vivo. Cancer Res. 51:1991;2340.
12. Kamni M., Augest C.S., Bunin N., Leahey A., Bayever E., Goldwein J. et al. Thiotepa, etoposide and fractionated total body irradiation as a preparative regimen prior to bone marrow transplantation for poor prognosis patients with neuroblastoma. Bone Marrow Transpl. 17:1996;911.
13. Bitron JD, Samuel B, Klein L, Hanaver S, Johnson L, Martinez J, et al. Tandem high dose chemotherapy supported by hematopoietic progenitor cells yields prolonged survival in stage IV breast cancer. Bone Marrow Transpl. 15:157.
14. Emanuel N.M., Konovalova N.P., Djachovakaya R.F. Toxicity, antitumor activity and pharmacokinetics of labelled thiotepa analogs. Cancer Treat. Rep. 60:1976;1605.
15. Odwyer P.J., Lacreat F., Engstrom P.F., Peter R., Tartaglia L., Cole D. et al. Phase I pharmacokinetics and reevaluation of thiotepa. Cancer Res. 51:1991;3171.
16. Heiderman R.L., Cole D., Bales F. Phase I pharmacokinetic evaluation of thiotepa in the cerebrospinal fluid and plasma of pediatric patients, evidenced for dose dependent plasma clearance of thiotepa. Cancer Res. 49:1989;736.
17. Wolf S.N., Herzig R.H., Fay J.W. High dose of thiotepa with autologous bone marrow transplantation: Phase I studies. Sem. Oncol. 17:1990;2.
18. Naparstek E., Or R., Nagler A., Cividalli G., Engelhard D., Aker N.M.N. et al. T-cell depleted allogeneic bone marrow transplantation for acute leukemia using CAMPATH-1 antibodies and post transplant administration of donor's peripheral blood lymphocytes for prevention of relapse. Br. J. Haematol. 89:1995;506.
19. Jeffrey A., Wilson V., Thein S.L. Hypervariable minisatellite regions in human DNA. Nature. 314:1985;67.
20. Wong Z., Wilson V., Patel I., Povey S., Jeffrey A.J. Characterization of a panel of highly variable minisatellites cloned from human DNA. Ann. Human Genet. 51:1987;269.
21. Pugatsch T., Oppenheim A., Slavin S. Improved single-step PCR assay for sex identification post allogeneic sex-mismatched BMT. Bone Marrow Transpl. 17:1996;273.
22. Bearman S.I., Appelbaum F.R., Buckner C.D. Regimen related toxicity in patients undergoing bone marrow transplantation. J. Clin. Oncol. 6:1988;1562.
23. Kaplan E., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457.
24. Slavin S., Naparstek E., Nagler A., Ackerstein A., Samuel S., Kapelushnik J. et al. Allogeneic cell therapy with donor peripheral blood cells and recombinant human interleukin-2 to treat leukemia relapse after allogeneic bone marrow transplantation. Blood. 87:1996;2195.
25. Spitzer G.R., Cottler F.M., Torriso J. Escalating doses of etoposide with cyclophosphamide and fractionated total body irradiation or busulfan as conditioning for bone marrow transplantation. Bone Marrow Transpl. 4:1989;559.
26. Devine M., Geller B., Holland K., Wingard R., Sarai R. New preparative regimens with diaziquone or cytarabine in combination with busulfan and cyclophosphamide. Sem. Oncol. 20:1995;56.
27. Geller R.B., Myers S., Devine S., Larson A., Williams F., Park C.L. et al. Phase I study of busulfan cyclophosphamide and timed sequential escalating doses of cytarabine followed by bone marrow transplantation. Bone Marrow Transpl. 9:1992;41.
28. Papadopoulos E.B., Carabasi M.H., Castromalaspina H., Childs B.H., Mackinnon S., Boulad F. et al. T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia. Freedom from relapse in the absence of graft versus host disease. Blood. 91:1998;1083.
29. Terenzi A., Lubin J., Lapidot T., Salomon O., Faktorowich Y., Rabi I. et al. Enhancement of T-cell-depleted bone marrow allografts in mice by thiotepa. Transplantation. 50:1990;717.
30. Down J.D., Westerhof G.R., Boudewijn A., Setroikromo R., Ploemacher R.E. Thiotepa improves allogeneic bone marrow engraftment without enhancing stem cell depletion in irradiated mice. Bone Marrow Transpl. 21:1998;327.
31. Aversa F., Pelicci P.G., Terenzi A., Carotti A., Felicini R., Mencarelli A. et al. Results of T-depleted BMT in chronic myelogenous leukaemia after a conditioning regimen that included thiotepa. Bone Marrow Transpl. 7(Suppl 2):1991;24.
32. Jacobs P., Wood L., Fullard L., Waldmann H., Hale G. T-cell depletion by exposure to Campath-1G in vitro prevents graft-versus-host disease. Bone Marrow Transpl. 13:1994;763.
33. Przepiorka D., Ippoliti C., Giralt S., Van Beisen K., Mehra R., Deisseroth A.B. et al. A phase I-II study of high dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic bone marrow transplantation. Bone Marrow Transpl. 14:1994;449.
34. Przepiorka D., Ippoliti C., Khouri I., Anderlini P., Mehra R., Giralt S. et al. Allogeneic transplantation for advanced leukemia: improved short-term outcome with blood stem cell grafts and tacrolimus. Transplantation. 62:1996;1806.
35. Dimopoulos M.A., Alexanian R., Przepiorka D., Hester J., Andersson B., Giralt S. et al. Thiotepa, busulfan and cyclophosphamide: A new preparative regimen for autologous bone marrow or blood stem cell transplantation in high risk multiple myeloma. Blood. 82:1993;2324.
36. Przepiorka D., Dimopoulos M., Smith J., Ippoliti C., Diener K., Luna M. et al. Thiotepa, busulfan and cyclophosphamide as a new preparative regimen for marrow transplantation: risk factors for early regimen related toxicity. Ann. Hematol. 68:1994;183.
37. Przepiorka D., Madden T., Ippoliti C., Estrou Z., Dimopoulos M. Dosing of thiotepa for myeloablative therapy. Cancer Chemother. Pharmacol. 37:1995;155.
38. Shulman H.M., Hinterberger W. Hepatic veno-occlusive disease-liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transpl. 10:1992;197.